Reduced susceptibility of Candida Albicans clinical isolates to azoles and detection of mutations in the ERG11 gene

Diagnostic Microbiology and Infectious Disease

Volumn 77, Issue 4, 2013, Pages 327-329

  Zhang, Lei ^a   Yang, Hai Fei ^a   Liu, Yan Yan ^b   Xu, Xi Hai ^a,b   Ye, Ying ^a,b   Li, Jia Bin ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Center for Surveillance of Bacterial Resistance   (China)

Author keywords

Azoles; Candidiasis; Drug resistance; MICs

Indexed keywords

FLUCONAZOLE; GENOMIC DNA; ITRACONAZOLE; VORICONAZOLE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CHINA; DNA SEQUENCE; ERG11 GENE; FUNGAL GENE; FUNGUS ISOLATION; GENE MUTATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AZOLES; CANDIDIASIS; DRUG RESISTANCE; MICS;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMERASE CHAIN REACTION;

EID: 84887610396     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.08.018     Document Type: Article

References (21)

1. Al-Fattani M.A., Douglas L.J. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol 2006, 55:999-1008.
2. Andes D., Nett J., Oschel P., Albrecht R., Marchillo K., Pitula A. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 2004, 72:6023-6031.
3. Baillie G.S., Douglas L.J. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 2000, 46:397-403.
4. Chau A.S., Mendrick C.A., Sabatelli F.J., Loebenberg D., McNicholas P.M. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004, 48:2124-2131.
5. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard-third edition. CLSI document M27-A3 2008, Clinical and Laboratory Standards Institute (CLSI), CLSI, Wayne, PA.
6. Kakeya H., Miyazaki Y., Miyazaki H., Nyswaner K., Grimberg B., Bennett J.E. Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother 2000, 44:2985-2990.
7. Lee M.K., Williams L.E., Warnock D.W., Arthington-Skaggs B.A. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004, 53:217-224.
8. Li X., Brown N., Chau A.S., López-Ribot J.L., Ruesga M.T., Quindos G., et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004, 53:74-80.
9. Maebashi K., Kudoh M., Nishiyama Y., Makimura K., Uchida K., Mori T., et al. A novel mechanism of fluconazole resistance associated with fluconazole sequestration in Candida albicans isolates from a myelofibrosis patient. Microbiol Immunol 2002, 46:317-326.
10. Maebashi K., Kudoh M., Nishiyama Y., Makimura K., Kamai Y., Uchida K., et al. Proliferation of intracellular structure corresponding to reduced affinity of fluconazole for cytochrome P-450 in two low-susceptibility strains of Candida albicans isolated from a Japanese AIDS patient. Microbiol Immunol 2003, 47:117-124.
11. Marichal P., Koymans L., Willemsens S., Bellens D., Verhasselt P., Luyten W., et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999, 145:2701-2713.
12. Martínez M., López-Ribot J.L., Kirkpatrick W.R., Bachmann S.P., Perea S., Ruesga M.T., et al. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother 2002, 49:515-524.
13. McCullough M.J., Clemons K.V., Stevens D.A. Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol 1999, 37:417-421.
14. Park S., Perlin D.S. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist 2005, 11:232-238.
15. Perea S., López-Ribot J.L., Kirkpatrick W.R., McAtee R.K., Santillán R.A., Martínez M., et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001, 45:2676-2684.
16. Sanglard D., Ischer F., Parkinson T., Falconer D., Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003, 47:2404-2412.
17. White T.C., Holleman S., Dy F., Mirels L.F., Stevens D.A. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002, 46:1704-1713.
18. Xiao L., Madison V., Chau A.S., Loebenberg D., Palermo R.E., McNicholas P.M. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004, 48:568-574.
19. Xu Y., Chen L., Li C. Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother 2008, 61:798-804.
20. Ying Y., Zhao Y., Hu X., Cai Z., Liu X., Jin G., et al. In vitro fluconazole susceptibility of 1,903 clinical isolates of Candida albicans and the identification of ERG11 mutations. Microb Drug Resist 2013, 19:266-273.
21. Zhu D.M., Zhang Y.Y., Wang F. Surveillance of resistance to fluconazole and voriconazole in Candida isolates from 5 hospitals in China. Chin J Infect Chemother 2007, 7:14-18.